The CA19-9/IgG4 ratio distinguishes between cholangiocarcinoma and IgG4-related cholangitis among patients with high IgG4 levels
Résumé fourni par la source
Both immunoglobulin G4 (IgG4)-related cholangitis (IRC) and cholangiocarcinoma (CCA) patients can have biliary strictures, and a serum IgG4 concentration ≥135 mg/dL leads to a diagnostic dilemma. We aimed to identify alternative serum markers to distinguish CCA from IRC. Patients with biliary stricture and a serum IgG4 concentration ≥135 mg/dL (n = 131) were enrolled in a tertiary care center (2008–2023). Of the 102 IRC patients (median age: 66 years), 91 (89.2%) were males; of the 29 CAA patients (mean age: 68 years), 21 (72.4%) were males. CCA patients presented lower serum IgG4 (median: 176 vs. 734 mg/dL, p < 0.001), higher carbohydrate antigen 19-9 (CA19-9) (391 vs. 46.2 U/mL, p < 0.001) and a higher neutrophil‒lymphocyte ratio (NLR) (4.8 vs. 2.8, p < 0.001) than IRC patients. The NLR (95% CIOR: 1.035–2.623), CA19-9 (1.001–1.023) and IgG4 (0.974–0.999) were independently associated with a diagnosis of CCA. In differentiating CCA from IRC, the areas under the receiver operating characteristic curve (AUROCs) of the NLR (cutoff >3.45), CA19-9 (cutoff >148 U/mL), IgG4 (cutoff ≤421 mg/dL) and the CA19-9/IgG4 ratio (cutoff >0.327) were 0.748, 0.857, 0.907 and 0.942, respectively. To predict CCA, CA19-9/IgG4 had a greater AUROC than CA19-9 ( p = 0.0003) and the NLR ( p = 0.001); IgG4 had a greater AUROC than the NLR ( p = 0.0107), and the performance of CA19-9/IgG4 was better than that of IgG4 (Z value = 1.2688). In addition to the serum NLR, CA19-9, and IgG4 levels, the CA19-9/IgG4 ratio (cutoff ≥0.327) is a feasible marker with good performance for identifying CCA in patients with serum IgG4 levels ≥135 mg/dL and biliary stricture.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- The CA19-9/IgG4 ratio distinguishes between cholangiocarcinoma and IgG4-related cholangitis among patients with high IgG4 levels
- Date Crossref
- 01/04/2026
- Éditeur
- Elsevier BV
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude et ne compte pas comme une seconde source scientifique indépendante.
Institutions déclarées
Une affiliation ne permet pas de déduire la nationalité d’un auteur.